Patents by Inventor Alejandro Mas Monteys

Alejandro Mas Monteys has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PROMOTER COMPOSITIONS
    Publication number: 20160022837
    Abstract: An isolated promoter sequence comprising a nucleic acid of between 600 and 1700 nucleotides in length having at least 90% identity to SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, or SEQ ID NO:7.
    Type: Application
    Filed: March 6, 2014
    Publication date: January 28, 2016
    Applicant: UNIVERSITY OF IOWA RESEARCH FOUNDATION
    Inventors: Beverly L. Davidson, Edgardo Rodriguez, Alejandro Mas Monteys
  • RNA interference suppression of neurodegenerative diseases and methods of use thereof
    Patent number: 9169483
    Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules.
    Type: Grant
    Filed: July 2, 2013
    Date of Patent: October 27, 2015
    Assignee: University of Iowa Research Foundation
    Inventors: Beverly L. Davidson, Alejandro Mas Monteys, Ryan L. Boudreau
  • REDUCTION OF OFF-TARGET RNA INTERFERENCE TOXICITY
    Publication number: 20140303362
    Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity.
    Type: Application
    Filed: August 27, 2013
    Publication date: October 9, 2014
    Applicant: University of Iowa Research Foundation
    Inventors: Beverly L. Davidson, Alejandro Mas Monteys, Jodi L. McBride, Ryan Boudreau
  • RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF
    Publication number: 20140163214
    Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules.
    Type: Application
    Filed: July 2, 2013
    Publication date: June 12, 2014
    Applicant: University of Iowa Research Foundation
    Inventors: Beverly L. Davidson, Alejandro Mas Monteys, Ryan L. Boudreau
  • Reduction of off-target RNA interference toxicity
    Patent number: 8524881
    Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity.
    Type: Grant
    Filed: July 18, 2012
    Date of Patent: September 3, 2013
    Assignee: University of Iowa Research Foundation
    Inventors: Beverly L. Davidson, Alejandro Mas Monteys, Jodi L. McBride, Ryan Boudreau
  • RNA interference suppression of neurodegenerative diseases and methods of use thereof
    Patent number: 8487088
    Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules.
    Type: Grant
    Filed: December 23, 2010
    Date of Patent: July 16, 2013
    Assignee: University of Iowa Research Foundation
    Inventors: Beverly L. Davidson, Alejandro Mas Monteys, Ryan L. Boudreau
  • REDUCTION OF OFF-TARGET RNA INTERFERENCE TOXICITY
    Publication number: 20120283424
    Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity.
    Type: Application
    Filed: July 18, 2012
    Publication date: November 8, 2012
    Applicant: University of Iowa Research Foundation
    Inventors: Beverly L. Davidson, Alejandro Mas Monteys, Jodi L. McBride, Ryan Boudreau
  • Reduction of off-target RNA interference toxicity
    Patent number: 8258286
    Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity.
    Type: Grant
    Filed: May 29, 2008
    Date of Patent: September 4, 2012
    Assignee: University of Iowa Research Foundation
    Inventors: Beverly L. Davidson, Alejandro Mas Monteys, Jodi L. McBride, Ryan Boudreau
  • RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF
    Publication number: 20110244562
    Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules.
    Type: Application
    Filed: December 23, 2010
    Publication date: October 6, 2011
    Applicant: University of Iowa Research Foundation
    Inventors: Beverly L. Davidson, Alejandro Mas Monteys, Ryan L. Boudreau
  • REDUCTION OF OFF-TARGET RNA INTERFERENCE TOXICITY
    Publication number: 20090130751
    Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence, and methods of using these RNAi molecules to reduce off-target toxicity.
    Type: Application
    Filed: May 29, 2008
    Publication date: May 21, 2009
    Inventors: Beverly L. Davidson, Alejandro Mas Monteys, Jodi L. McBride, Ryan Boudreau
  • RNA INTERFERENCE SUPPRESSION OF NEURODEGENERATIVE DISEASES AND METHODS OF USE THEREOF
    Publication number: 20090036395
    Abstract: The present invention is directed to RNA interference (RNAi) molecules targeted against a nucleic acid sequence that encodes poly-glutamine repeat diseases, and methods of using these RNAi molecules.
    Type: Application
    Filed: April 28, 2008
    Publication date: February 5, 2009
    Inventors: Beverly L. Davidson, Alejandro Mas Monteys
  • Joint utilization of the insulin gene and the glucokinase gene in the development of therapeutic approaches for diabetes mellitus
    Publication number: 20040055023
    Abstract: This invention relates to a double transgenic animal that simultaneously expresses the gene or the cDNA (complementary DNA) of insulin and the gene or the cDNA (complementary DNA) of glucokinase directed by a promoter or fusion of promoters which permit insulin and glucokinase to be expressed in muscle and its use in the development of therapeutic approximations for diabetes mellitus.
    Type: Application
    Filed: October 20, 2003
    Publication date: March 18, 2004
    Inventors: Fatima Bosch Tubert, Efren Riu Pastor, Pedro Jose Otaegui Goya, Maria del Tura Ferre Masferrer, Alejandro Mas Monteys